What Tempus AI (TEM) Said on Its Q3 Earnings Call

Tempus AI reported Q3 2026 revenue of $411.5 million, up 23% year over year, with growth in oncology diagnostics and data-and-applications services. The company raised its full-year revenue outlook and generated positive adjusted EBITDA during the quarter.

Analysis

The result strengthens the case that Tempus can monetize its oncology data alongside diagnostics, but the key question is whether data-and-applications growth is repeatable and sufficiently high quality to support durable economics—not whether one quarter cleared adjusted EBITDA. A diagnostics footprint could deepen the data asset and improve customer utility over time; the reverse is also true: weak test adoption, reimbursement pressure, or limited data-product renewal would undermine the flywheel. Competition from Guardant Health, Natera, and Exact Sciences makes evidence of differentiated adoption more important than broad AI positioning.

Near term, guidance credibility and the market’s expectations embedded in TEM’s price matter more than the reported growth rate; valuation and consensus data are not provided, so there is no basis here to call the shares cheap or the reaction mispriced. Over the next 1–3 months, verify the outlook’s implied quarterly cadence and whether growth is broad-based across diagnostics and data services. Over 6–18 months, the structural test is conversion of adjusted EBITDA into cash after stock-based compensation and investment needs. The contrarian risk is that investors capitalize adjusted profitability before cash generation is established; the upside risk to skeptics is a durable data business improving the economics of the diagnostics platform.

Key Decisions for Investors

• Do not chase a post-results gap on this information alone. Treat TEM as a watchlist long; consider entry on consolidation only if the next filing confirms the raised outlook is supported by sustained segment growth and improving cash conversion.
• Before sizing a position, verify segment-level growth, gross-margin trajectory, operating cash flow, stock-based compensation, receivables, and the reconciliation from adjusted EBITDA to GAAP results. These are the missing checks on earnings quality.
• For the next 1–3 months, reassess on guidance cadence and evidence of data-product renewals or adoption. A slowdown in either business line, weaker outlook, or widening cash burn would falsify the constructive thesis; continued growth with improving cash conversion would strengthen it.
• Avoid a peer short as a default hedge: the article provides no relative valuation or market-share evidence. If TEM materially outperforms on sentiment without corresponding cash-flow evidence, reduce exposure rather than assuming the AI narrative guarantees durable economics.